Health Economics Review最新文献

Objectives: Nepalese students in Japan surged from under 1,000 in 2008 to over 29,000 by 2019, driven by Japan's strategy of using student visas to fill unskilled labor gaps. This study examined the cost and benefit impact of the introduction of pre-entry tuberculosis (TB) screening policy, including testing and treatment for Japan and Nepal from 2014 to 2018.

Methods: This study used anonymous data of TB statistics of diagnosis and treatment from the Nepal Demographic and Health Survey and from Japan's Legal Affairs Bureau and Tuberculosis Surveillance Center. We used social cost-benefit analysis to examine the effect of the pre-entry TB screening policy on visas of Nepalese workers and students to Japan. Total cost, total benefit and net benefit for both countries were compared for the policy scenarios "With" and "Without", using net present value (NPV). In order to address parameter differences for uncertainty, we conducted sensitivity analysis using the Monte Carlo simulation with secondary transmission rate.

Results: Between 2014 and 2018 in Japan, net present value (NPV) of Nepalese students increased from USD 1.9 million to USD 3.1 million; likewise, NPV of Nepalese workers grew from USD 1.1 million to USD 3.2 million. From the perspective of Japan, the increase in NPV was greater than zero, meaning that the implementation of the policy could produce a benefit for Japan regarding prevention of an increase in new TB cases. The total NPV was USD -51.6 million, as pre-entry screening and treatment costs are incurred by both emigrants and the national health system.

Conclusions: Implementing a pre-entry TB screening policy for foreign migrants from high-burden countries such as Nepal could yield cost savings by reducing the incidence of newly diagnosed and potentially transmissible TB cases. Strong collaboration could ensure the follow-up and incentive for burden sharing of the implementation cost.

Risk adjustment formulas are essential in health insurance markets, as they mitigate risk selection incentives by aligning revenues with expected healthcare expenses based on enrollee characteristics. However, current formulas can underpredict spending for certain groups, leading to under-compensation for insurers and potentially affecting fairness, quality, and access to care. Many countries are exploring the addition of new variables to improve accuracy, but this can also weaken incentives for cost control. This paper illustrates a methodology approach to risk adjuster selection by using a penalized regression framework that explicitly incorporates the potential downsides of including specific variables. Drawing on a large dataset of over 10 million Colombian health insurance enrollees, we combine statistical estimation with expert assessment of each variable's susceptibility to gaming to construct a specification that limits gaming and maintains predictive accuracy.

Nigeria's growing digital health startup ecosystem has a lot of potential to fill in gaps in healthcare delivery, but many of these businesses fail to get off the ground after getting initial funding. This narrative review examines funding patterns from 2019 to 2025 and investigates why seed-stage investment often fails to translate into scaled impact. Investment reports, case studies of prominent Nigerian health-tech startups, and comparative insights from peer markets were synthesized. The analysis finds that despite a surge of seed funding and a record venture capital peak in 2021, few Nigerian digital health startups convert initial success into sustainable growth. Constraining factors include regulatory hurdles, infrastructural deficiencies, market trust barriers, talent gaps, and systemic health-sector limitations, challenges that mere capital infusion cannot overcome. Case narratives (e.g., Helium Health's regional expansion and 54gene's post-pandemic collapse) illustrate these dynamics. Key mechanisms to bridge the "post-seed" gap are discussed, ranging from strategic public-private partnerships to specialized follow-on funds, with lessons drawn from ecosystems like Kenya and India. Strengthening support beyond seed stages and addressing non-financial frictions will be crucial for Nigerian health-tech innovators to realize their full scale-up potential.

This paper examines how rural primary care physicians in China adjusted their practice patterns to pandemic-related financial pressures under a capitated global-budget model. Using township-hospital data, we find increased prescribing of Traditional Chinese Medicine (TCM) decoction pieces, with effects concentrated among habitual prescribers rather than converting occasional users into regular prescribers. Physicians also reduced both the number of drugs prescribed and the volume of services provided to cost-sharing outpatients, producing a 5% decline in average insurance payments per outpatient visit and potentially generating a greater surplus within the global-budget pool. By contrast, we observe no significant changes for self-paying outpatients, suggesting limited scope for physician-induced demand. These results underscore the role of physician agency in healthcare provision and highlight the importance of aligning financial incentives with policy goals. While drug reforms and managed-care models have contained expenditures, challenges remain in achieving adequate coverage for rural residents.

The pricing of new drugs plays a critical role in patient access by influencing where and when pharmaceutical companies choose to launch their products. The United States (US) operates a predominantly market-based pricing system, in which pharmaceutical companies set and manage drug prices under private health insurance. In contrast, Japan has a government-regulated drug pricing system under its National Health Insurance (NHI). On average, drug prices in the US are 3.2 times higher than those in Japan. The US system facilitates faster patient access to new drugs through rapid market entry, whereas market entry in Japan has often been delayed. To address this issue, the Japanese government introduced the Rapid Introduction Premium in April 2024, aiming to promote earlier launches of new drugs by narrowing the price gap with higher-priced markets such as the US. In this review, we provide an overview of the new drug pricing framework associated with the Rapid Introduction Premium.